PDCD1 and non-small cell lung carcinoma: The most relevant knowledge on the biological significance and clinical utility of T-cell repertoire analysis is emerging from the study on the safety and feasibility of neoadjuvant anti-PD-1 therapy in early stage (stage I, II, or IIIA) NSCLC (NCT02259621) [75].